Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2015—Siemens Healthcare has joined the CANCER-ID consortium, an initiative of the European Union’s Innovative Medicines Initiative, to explore the potential of blood-based biomarkers in the detection and treatment of cancer.
November 2015—CLSI released new and revised standards on method evaluation titled “A Framework for Using CLSI Documents to Evaluate Clinical Laboratory Measurement Procedures (EP19-Ed2).”
November 2015—Agena Bioscience introduced the Chip prep moduleto automate sample handling after polymerase chain reaction for the MassArray 96-well System. This enables laboratories to operate the MassArray System largely unattended for high-throughput, multiplex genetic analysis.
November 2015—Bio SB PolyDetector Systems are highly sensitive micropolymeric detection systems that allow for the demonstration of antigens in formalin-fixed, paraffin-embedded tissues, cryostat sections, blood smears, cytosmears, and cell preparations.
November 2015—Roche has launched the SeqCap EZ Med-Exome Target Enrichment Kit, a comprehensive whole exome sequencing solution designed to increase the discovery and detection of human genetic variants associated with disease while reducing sequencing costs. For research use only; not for use in diagnostic procedures.
November 2015—Nuclea Biotechnologies has met the requirements from the FDA for its Carbonic Anhydrase IX Automated immunohistochemistry kit as a class I in vitro diagnostic device for use on a Ventana Benchmark XT instrument.
November 2015—General Data Healthcare has introduced five products for the histology lab. The ID/Positive CL-04 Laser Cassette Marker offers permanent, indelible marking of tissue cassettes and slides with high-resolution text and barcodes and features four removable cassette magazines, each holding up to 70 cassettes, for a total of 280, which can be switched with magazines containing different cassette types or colors.
November 2015—Irvine Scientific received CE mark approval for its Human Serum Albumin Solution (100 mg/mL) in normal saline. HSA is used in assisted reproductive procedures as a protein supplement for gamete and embryo manipulation.
November 2015—Illumina has launched TruSight Tumor 15, a next-generation sequencing panel designed to identify sequence variants in 15 genes commonly associated with marketed therapeutics. The sequencing panel is optimized for damaged and degraded formalin-fixed, paraffin-embedded tumor samples, enabling low frequency somatic variant detection from limited nucleic acid inputs.
November 2015—Maine Standards released its Validate SP2 calibration verification/linearity test kit, which evaluates albumin, C-reactive protein, haptoglobin, and prealbumin in a human-serum–based matrix.
